ライフサイエンスコーパス: monocyte chemoattractant protein

1 eta and interleukin-6) and chemokine (MCP-1; monocyte chemoattractant protein).

2 creases in interleukin-6 (21%; P < 0.02) and monocyte chemoattractant protein 1 (14% decrease at 4 wk

3 Monocyte chemoattractant protein 1 (CCL2) is a recently

4 ll alpha chemoattractant (I-TAC/CXCL11), and monocyte chemoattractant protein 1 (CCL2) were measured

5 CD163 (sCD163) and soluble CD14 (sCD14), and monocyte chemoattractant protein 1 (CCL2) with subclinic

6 ssion of the fibrocyte recruiting chemokines monocyte chemoattractant protein 1 (MCP-1) and CXCL12, a

7 ed, there was a significant decrease in CCL2/monocyte chemoattractant protein 1 (MCP-1) and inflammat

8 stability of tumor necrosis factor alpha and monocyte chemoattractant protein 1 (MCP-1) but strongly

9 low-density lipoprotein (ox-LDL)-stimulated monocyte chemoattractant protein 1 (MCP-1) from macropha

10 d various levels of interleukin-8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) in response t

11 lammatory cytokines interleukin-8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) in response t

12 ssion of the inflammatory mediators CD36 and monocyte chemoattractant protein 1 (MCP-1) in the brain

13 While monocyte chemoattractant protein 1 (MCP-1) is known to b

14 Monocyte chemoattractant protein 1 (MCP-1) mediates acut

15 Although the M-CSF and monocyte chemoattractant protein 1 (MCP-1) mRNA levels w

16 Monocyte chemoattractant protein 1 (MCP-1) peaked postdi

17 Monocyte chemoattractant protein 1 (MCP-1) plays a pivot

18 We showed previously that monocyte chemoattractant protein 1 (MCP-1) was a critica

19 Recently, increased expression of monocyte chemoattractant protein 1 (MCP-1) was reported

20 ar adhesion molecule 1 (ICAM-1), E-selectin, monocyte chemoattractant protein 1 (MCP-1), and interleu

21 Of the 21 cytokines tested, monocyte chemoattractant protein 1 (MCP-1), keratinocyte

22 ter infection (day 2), interleukin 6 (IL-6), monocyte chemoattractant protein 1 (MCP-1), macrophage i

23 anulocyte colony-stimulating factor (G-CSF), monocyte chemoattractant protein 1 (MCP-1), macrophage i

24 s of IFN-gamma-inducible protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage i

25 IL-12, and IL-18; chemokines, such as IL-8, monocyte chemoattractant protein 1 (MCP-1), RANTES, and

26 rogenase, and inflammatory mediators such as monocyte chemoattractant protein 1 (MCP-1), TNF-alpha, a

27 lammatory mediators, including TNF-alpha and monocyte chemoattractant protein 1 (MCP-1).

28 gration via increased expression of IL-6 and monocyte chemoattractant protein 1 (MCP-1).

29 , we show that T. cruzi strongly upregulates monocyte chemoattractant protein 1 (MCP-1)/CCL2 and frac

30 l-derived factor 1alpha (SDF-1alpha)/CXCL12, monocyte chemoattractant protein 1 (MCP-1)/CCL2, and vas

31 Monocyte chemoattractant protein 1 (MCP-1/CCL2) is a pro

32 , S1P stimulated secretion of the chemokine, monocyte chemoattractant protein 1 (MCP-1/CCL2), from th

33 ctants were induced in the kidney, including monocyte chemoattractant protein 1 (MCP-1/CCL2), macroph

34 eoprotegerin (OPG) expression and increasing monocyte chemoattractant protein 1 (MCP1) expression in

35 rleukin-6 (Il-6), interleukin-1beta (Il-1b), monocyte chemoattractant protein 1 (Mcp1), and fibrosis-

36 mor necrosis factor alpha (TNF-alpha), CCL2 (monocyte chemoattractant protein 1 [MCP-1]), and CCL5 (R

37 6), and chemokine (C-C motif) ligand (CCL2) (monocyte chemoattractant protein 1 [MCP-1]).

38 ines (interleukin 6 [IL-6], IL-8, IL-1alpha, monocyte chemoattractant protein 1 [MCP-1], and colony-s

39 atory cytokines (interleukin-6 [IL-6], IL-8, monocyte chemoattractant protein 1 [MCP-1], and IL-1beta

40 adhesion molecule 1, soluble E-selectin, and monocyte chemoattractant protein 1 and cancer risk.

41 diponectin and leptin while reducing that of monocyte chemoattractant protein 1 and interleukin-8 by

42 eotaxin, IL-2, and IL-12 and the chemokines monocyte chemoattractant protein 1 and keratinocyte-deri

43 alveolar epithelial cells produced excessive monocyte chemoattractant protein 1 and reactive oxygen s

44 Systemic LDL oxidation and monocyte chemoattractant protein 1 and the expression of

45 In RAW264.7 cells, allosamidin elevated monocyte chemoattractant protein 1 and tumor necrosis fa

46 of tumor necrosis factor, interleukin-6, and monocyte chemoattractant protein 1 by spleen cells was a

47 12p40, interferon-inducible protein 10, and monocyte chemoattractant protein 1 concentrations, where

48 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein 1 in lumbar spinal cord

49 hyper-IgE syndrome generated lower levels of monocyte chemoattractant protein 1 in response to the pr

50 ction was strongly correlated with increased monocyte chemoattractant protein 1 levels (r = 0.396, P

51 educed IL-4, IL-5, IL-13, eotaxin, IL-8, and monocyte chemoattractant protein 1 production without af

52 ), monokine induced by interferon-gamma, and monocyte chemoattractant protein 1 were quantified as me

53 ellular protease plasmin cleaves mouse MCP1 (monocyte chemoattractant protein 1) at lysine 104, relea

54 of THP-1 monocytes to migrate toward MCP-1 (monocyte chemoattractant protein 1) depended upon Par3 a

55 necrosis factor alpha, interleukin-6, CCL2 (monocyte chemoattractant protein 1), and CCL5 (RANTES).

56 F-beta, connective tissue growth factor, and monocyte chemoattractant protein 1), and epithelial-to-m

57 emokine, C-C motif chemokine ligand 2 (CCL2; monocyte chemoattractant protein 1), termed mNOX-E36, in

58 induced inflammation (tumor necrosis factor, monocyte chemoattractant protein 1, and chemokine [C-X-C

59 s of myeloperoxidase, tumor necrosis factor, monocyte chemoattractant protein 1, and gamma interferon

60 eukin 1beta (IL-1beta), IL-6, CXCL1/KC, CCL2/monocyte chemoattractant protein 1, and granulocyte colo

61 terleukin-6, keratinocyte-derived chemokine, monocyte chemoattractant protein 1, and interleukin-10),

62 e, with extremely high mRNA levels for IL-8, monocyte chemoattractant protein 1, and macrophage infla

63 asminogen activator receptor, interleukin-6, monocyte chemoattractant protein 1, and matrix metallopr

64 nterferon gamma-inducible protein of 10 kDa, monocyte chemoattractant protein 1, growth-related oncog

65 accumulation, apoptosis, necrotic cores, and monocyte chemoattractant protein 1, interleukin 1beta, i

66 ing factor were significantly reduced, while monocyte chemoattractant protein 1, macrophage inflammat

67 erestingly, higher levels of interleukin 22, monocyte chemoattractant protein 1, TNF-alpha, and IP-10

68 ential of mouse melanoma cells in HDAC3- and monocyte chemoattractant protein 1-(MCP1)-dependent mann

69 eta), tumor necrosis factor (TNF), IL-6, and monocyte chemoattractant protein 1.

70 ression of proinflammatory interleukin 6 and monocyte chemoattractant protein 1.

71 terferon [IFN-gamma], and IL-6), chemokines (monocyte chemoattractant protein 1/CCL-2, macrophage inf

72 of histamine, cytokines, and the chemokines monocyte chemoattractant protein 1/CCL2, macrophage infl

73 biomarkers (glial fibrillary acidic protein, monocyte chemoattractant protein 1/chemokine (C-C motif)

74 glial fibrillary acidic protein (p = 0.002), monocyte chemoattractant protein 1/chemokine (C-C motif)

75 ing tumor necrosis factor alpha (TNF-alpha); monocyte chemoattractant protein 1; macrophage inflammat

76 ce was observed, certain chemokines (RANTES, monocyte chemoattractant protein 1[MCP-1], and IP-10) we

77 10]), and proinflammatory cytokines (MCP-1 [monocyte chemoattractant protein 1], MIP-1alpha/beta [ma

78 we show that TXA(2) mimetic, I-BOP, induced monocyte chemoattractant protein -1(MCP-1)/chemokine (C-

79 or necrosis factor-alpha (-16% versus +12%), monocyte chemoattractant protein-1 (-13% versus +0.2%),

80 ations of inflammatory biomarkers, including monocyte chemoattractant protein-1 (adjusted OR 9.0 [95%

81 d PGE(2)-induced production of the chemokine monocyte chemoattractant protein-1 (CCL2), which was lin

82 an IC50 of 22.8 nM but was inactive against monocyte chemoattractant protein-1 (CCL2)-mediated calci

83 ion, associated with 38% reduced circulating monocyte chemoattractant protein-1 (MCP-1) and 36% lower

84 6), tumor necrosis factor-alpha (TNF-alpha), monocyte chemoattractant protein-1 (MCP-1) and C-reactiv

85 Very high plasma levels of monocyte chemoattractant protein-1 (MCP-1) and interleuk

86 ited TNF-alpha-induced inflammatory factors, monocyte chemoattractant protein-1 (MCP-1) and interleuk

87 so increased levels of inflammatory cytokine monocyte chemoattractant protein-1 (MCP-1) and MCP-1 ind

88 h as interleukin (IL)-6, IL-1beta, IL-8, and monocyte chemoattractant protein-1 (MCP-1) and the secre

89 d and is accompanied by increases in mRNA of monocyte chemoattractant protein-1 (MCP-1) and tumor nec

90 VSMC stimulated by TGF-beta/AdSmad3 revealed monocyte chemoattractant protein-1 (MCP-1) as a likely f

91 pirfenidone impaired macrophage migration to monocyte chemoattractant protein-1 (MCP-1) as well as IL

92 an obligate dimeric mutant of the chemokine monocyte chemoattractant protein-1 (MCP-1) by substituti

93 Monocyte chemoattractant protein-1 (MCP-1) directs migra

94 uced Src and STAT3 tyrosine phosphorylation, monocyte chemoattractant protein-1 (MCP-1) expression an

95 JNK as the exclusive mediator of FFA-induced monocyte chemoattractant protein-1 (MCP-1) expression in

96 15(S)-HETE also induced monocyte chemoattractant protein-1 (MCP-1) expression vi

97 Monocyte chemoattractant protein-1 (MCP-1) is involved i

98 atment with p38 MAPK inhibitor reduced renal monocyte chemoattractant protein-1 (MCP-1) levels, the n

99 a murine model of an arteriovenous fistula, monocyte chemoattractant protein-1 (MCP-1) mRNA and prot

100 These cells produced monocyte chemoattractant protein-1 (MCP-1) upon PIM trea

101 The chemokine monocyte chemoattractant protein-1 (MCP-1) was cooperati

102 Previously, monocyte chemoattractant protein-1 (MCP-1) was demonstra

103 mobility mass spectrometry (IMMS) to analyze monocyte chemoattractant protein-1 (MCP-1), a CC chemoki

104 Monocyte chemoattractant protein-1 (MCP-1), a CC-motif c

105 in HK-2 cells to stimulate the production of monocyte chemoattractant protein-1 (MCP-1), a key chemok

106 -1beta (IL-1beta), the cytokines IL-8, IL-6, monocyte chemoattractant protein-1 (MCP-1), and growth-r

107 yperactivation of ERK and p38 in response to monocyte chemoattractant protein-1 (MCP-1), and increase

108 phage accumulation, diminished expression of monocyte chemoattractant protein-1 (MCP-1), and lower le

109 activation-regulated chemokine (TARC), IL-8, monocyte chemoattractant protein-1 (MCP-1), and murine b

110 Stroke outcome, expression of brain CD36, monocyte chemoattractant protein-1 (MCP-1), CCR2, and pl

111 The role of the chemokine, monocyte chemoattractant protein-1 (MCP-1), elevated in

112 The expression of monocyte chemoattractant protein-1 (MCP-1), intercellula

113 d beta2-integrins, cyclooxygenase-2 (COX-2), monocyte chemoattractant protein-1 (MCP-1), interleukin-

114 We have previously shown that the chemokine, monocyte chemoattractant protein-1 (MCP-1), is a mediato

115 Analysis of mice lacking monocyte chemoattractant protein-1 (MCP-1), MCP-3, MCP-5

116 ge inflammatory protein-1alpha (MIP-1alpha), monocyte chemoattractant protein-1 (MCP-1), regulated on

117 n-gamma-inducible protein of 10 kDa (IP-10), monocyte chemoattractant protein-1 (MCP-1), tumor necros

118 netic basis of circulating concentrations of monocyte chemoattractant protein-1 (MCP-1), we conducted

119 n WAT and an increase of the proinflammatory monocyte chemoattractant protein-1 (MCP-1).

120 appaB pathway, which increased production of monocyte chemoattractant protein-1 (MCP-1).

121 expression of the proinflammatory cytokine, monocyte chemoattractant protein-1 (MCP-1).

122 high levels of interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1 (MCP-1).

123 and selective induction of the CC chemokine monocyte chemoattractant protein-1 (MCP-1).

124 tion, as measured by decreased expression of monocyte chemoattractant protein-1 (MCP-1).

125 chemotaxis can be signaled by the chemokine monocyte chemoattractant protein-1 (MCP-1)/CCL2 (CC chem

126 that interact with the oligomeric chemokine Monocyte Chemoattractant Protein-1 (MCP-1)/CCL2 with dif

127 rated increased expression of iNOS, C1r, and monocyte chemoattractant protein-1 (MCP-1); MCP-1 expres

128 RK) to mechanically trigger the secretion of monocyte chemoattractant protein-1 (MCP-1, also known as

129 ort the expression profile of the chemokine, monocyte chemoattractant protein-1 (MCP-1, CCL2), during

130 Genetic deletions of monocyte chemoattractant protein-1 (MCP-1, CCL2), fracta

131 to chronic pain includes the upregulation of monocyte chemoattractant protein-1 (MCP-1/CCL2) and its

132 proinflammatory cytokine IL-6 and chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2) in respo

133 keratinocytes up-regulated the expression of monocyte chemoattractant protein-1 (MCP-1/CCL2), TNFalph

134 CCR2 on its interactions with the chemokine monocyte chemoattractant protein-1 (MCP-1/CCL2).

135 ic pain, and mice overexpressing its ligand, monocyte chemoattractant protein-1 (MCP1; also known as

136 kin-6 (P=0.01), isoprostanes (P=0.0002), and monocyte chemoattractant protein-1 (P=0.008); SAT only r

137 hly associated with urinary isoprostanes and monocyte chemoattractant protein-1 (SAT versus VAT compa

138 ange messenger RNA: interleukin-1beta = 7.6, monocyte chemoattractant protein-1 = 15.3, and tumor nec

139 ls of IL-6, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 after stimulation wit

140 n the vascular wall (decreased production of monocyte chemoattractant protein-1 and activation of p38

141 ukin-6, tumor necrosis factor) and adaptive (monocyte chemoattractant protein-1 and CXCL10 chemokines

142 plasia and pro-inflammatory gene expression (monocyte chemoattractant protein-1 and cytokine-induced

143 or necrosis factor-alpha, interleukin-6, and monocyte chemoattractant protein-1 and decreased M2 mark

144 ry and proproliferative mediators, including monocyte chemoattractant protein-1 and hypoxia-inducible

145 Seeded BMCs secreted significant amounts of monocyte chemoattractant protein-1 and increased early m

146 d at the promoters of the inflammatory genes monocyte chemoattractant protein-1 and interleukin-6 in

147 in significantly reduced production of serum monocyte chemoattractant protein-1 and interleukin-6 lev

148 lial selectin surface expression and reduced monocyte chemoattractant protein-1 and interleukin-6 pro

149 -infected MSKO mouse livers had: (1) greater monocyte chemoattractant protein-1 and macrophage inflam

150 Unlike WT mice, induction of monocyte chemoattractant protein-1 and macrophage migrat

151 ased expression of the proinflammatory gene, monocyte chemoattractant protein-1 and matrix metallopro

152 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 and reduced mRNA and

153 25(OH)(2)D(3) supplementation also inhibited monocyte chemoattractant protein-1 and stimulated adipon

154 macrophages showed reduced migration toward monocyte chemoattractant protein-1 and transmigration th

155 uction of key proatherogenic factors such as monocyte chemoattractant protein-1 and tumor necrosis fa

156 h plaque stabilization and downregulation of monocyte chemoattractant protein-1 and ubiquitin.

157 okine (C-C motif) ligand 5 and expression of monocyte chemoattractant protein-1 and vascular cell adh

158 oliferating cell nuclear antigen+ cells, and monocyte chemoattractant protein-1 and vascular cell adh

159 sAPPbeta) and two neuroinflammatory markers (monocyte chemoattractant protein-1 and YKL-40) were meas

160 NA levels of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 as 129/B6-ApoE(-/-) c

161 ficantly with matrix metalloproteinase-3 and monocyte chemoattractant protein-1 at baseline, biomarke

162 iR-132 and demonstrated that miR-132 induces monocyte chemoattractant protein-1 at least in part via

163 from WKY rats synthesized significantly more monocyte chemoattractant protein-1 basally and after sti

164 7/BL6 mice, markedly augmented the levels of monocyte chemoattractant protein-1 bound to RBCs, which

165 osis factor-alpha, IL-1beta, IL-6, IL-8, and monocyte chemoattractant protein-1 by co-cultured dendri

166 ts contained increased leptin, resistin, and monocyte chemoattractant protein-1 compared with plasma

167 Monocyte chemoattractant protein-1 concentrations in nas

168 nside-out activation of beta(2) integrins by monocyte chemoattractant protein-1 did not change IL-13-

169 y reduced hepatic inflammation, particularly monocyte chemoattractant protein-1 expression and macrop

170 ell as vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 expression in endothe

171 n, normal T cell expressed and secreted) and monocyte chemoattractant protein-1 expression induced by

172 tin on vascular cell adhesion molecule-1 and monocyte chemoattractant protein-1 expression.

173 ating vascular cell adhesion molecule -1 and monocyte chemoattractant protein-1 expressions.

174 n, normal T cell expressed and secreted) and monocyte chemoattractant protein-1 in a mouse model of o

175 tic lesion areas and decreased expression of monocyte chemoattractant protein-1 in the aorta as compa

176 amma, tumor necrosis factor-alpha, IL-8, and monocyte chemoattractant protein-1 in the spleen.

177 Monocyte chemoattractant protein-1 is a chemokine recrui

178 eased plasma tumor necrosis factor-alpha and monocyte chemoattractant protein-1 levels in Tg-hCBS apo

179 igation and puncture, and interleukin 10 and monocyte chemoattractant protein-1 levels were higher in

180 indicated Cr elevations correlated with CSF monocyte chemoattractant protein-1 levels.

181 ed plasma interleukin-6, interleukin-10, and monocyte chemoattractant protein-1 levels.

182 essed and secreted, T-cell activation-3, and monocyte chemoattractant protein-1 mRNAs were lower comp

183 SkMCs released IL-6, IL-8, and monocyte chemoattractant protein-1 on Hsp60 stimulation.

184 found a 3-fold increase in interleukin-6 and monocyte chemoattractant protein-1 production by G2A(-/-

185 Pio also did not attenuate Ang II-induced monocyte chemoattractant protein-1 production in PPARgam

186 responses to TLR2 and TLR4 ligands, reduced monocyte chemoattractant protein-1 production, and preve

187 ammation, limits neutrophils recruitment and monocyte chemoattractant protein-1 production, thus redu

188 yte/macrophage migration rather than reduced monocyte chemoattractant protein-1 production.

189 cts of Klotho signaling on interleukin-8 and monocyte chemoattractant protein-1 promoter recruitment

190 Monocyte chemoattractant protein-1 provides independent

191 This was associated with marked increase in monocyte chemoattractant protein-1 synthesis in WKY glom

192 Monocyte chemoattractant protein-1 was measured at basel

193 Given its unique role, future studies into monocyte chemoattractant protein-1's exact role during s

194 he TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattractant protein-1) and GM-CSF genes, an

195 ed with increased renal expression of MCP-1 (monocyte chemoattractant protein-1) and VLA-4 (very-late

196 ray indicated that the chemokine CCL2/MCP-1 (monocyte chemoattractant protein-1) was strongly induced

197 remote myocardium (e.g., 12-fold increase of monocyte chemoattractant protein-1), although levels wer

198 increases in CC chemokine ligand 2 (CCL2, or monocyte chemoattractant protein-1), an important macrop

199 CI and other wild type CC chemokines, MCP-1 (monocyte chemoattractant protein-1), MIP-1beta, and RANT

200 iated inflammatory mediators (in particular, monocyte chemoattractant protein-1).

201 m levels of CD40 ligand, serum amyloid A and monocyte chemoattractant protein-1, (b) limited evidence

202 5%, P < 0.002; interleukin-6, 13%, P < 0.01; monocyte chemoattractant protein-1, 10%, P < 0.0006) and

203 increased CD68, tumor necrosis factor alpha, monocyte chemoattractant protein-1, alpha-smooth muscle

204 ene and protein expression of tissue factor, monocyte chemoattractant protein-1, and cyclooxygenase-2

205 ated lipocalin, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and fractional hypox

206 on- gamma , interleukin [IL]-4, IL-10, IL-6, monocyte chemoattractant protein-1, and growth-regulated

207 with statistically different levels of IL-6, monocyte chemoattractant protein-1, and heat-shock prote

208 ed secretion of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and interleukin-12.

209 lecule-1, intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and interleukin-17A;

210 increased expression of inflammatory genes, monocyte chemoattractant protein-1, and interleukin-6, a

211 irculating levels of P-selectin, E-selectin, monocyte chemoattractant protein-1, and macrophage conte

212 atory cytokines tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and macrophage infla

213 lating factor, keratinocyte chemoattractant, monocyte chemoattractant protein-1, and macrophage infla

214 L-8, IL-10, interferon-inducible protein-10, monocyte chemoattractant protein-1, and tumor necrosis f

215 roinflammatory cytokines (interleukin-1beta, monocyte chemoattractant protein-1, and tumor necrosis f

216 neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and tumor necrosis f

217 neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and tumor necrosis f

218 ession of intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and vascular endothe

219 IL-8, granulocyte colony-stimulating factor, monocyte chemoattractant protein-1, C-reactive protein,

220 growth factor, hepatocyte growth factor and monocyte chemoattractant protein-1, contributing to deve

221 enes such as tumor necrosis factor-alpha and monocyte chemoattractant protein-1, decreased AT inflamm

222 proinflammatory mediators interleukin-6 and monocyte chemoattractant protein-1, fibroblast growth fa

223 binding oligomerization domain containing-2, monocyte chemoattractant protein-1, IL-2, and IL-12p40 i

224 micked by stimulation of Hmox1(+/+) SCs with monocyte chemoattractant protein-1, IL-6, IL-1beta, and

225 tate dehydrogenase, as well as expression of monocyte chemoattractant protein-1, IL-6, IL-1beta, and

226 Five inflammatory markers (IL-6, IL-8, monocyte chemoattractant protein-1, interferon-gamma-ind

227 inflammatory response through alteration of monocyte chemoattractant protein-1, interleukin-1beta, a

228 of cytokines keratinocyte-derived chemokine, monocyte chemoattractant protein-1, interleukin-6 (IL-6)

229 m TK-/- mice exhibited blunted production of monocyte chemoattractant protein-1, interleukin-6, and m

230 oduction of cytokines and chemokines, namely monocyte chemoattractant protein-1, interleukin-6, and m

231 icantly higher levels of expression of cKIT, monocyte chemoattractant protein-1, interleukin-6, strom

232 ion, as denoted by the reduced expression of monocyte chemoattractant protein-1, intracellular adhesi

233 cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1, is markedly increase

234 ial protein expression of interleukin-18 and monocyte chemoattractant protein-1, key mediators of car

235 protein-1alpha, and C-reactive protein, and monocyte chemoattractant protein-1, macrophage inflammat

236 Upregulation of monocyte chemoattractant protein-1, macrophage inflammat

237 terferon-gamma inducible protein-10 [IP-10], monocyte chemoattractant protein-1, macrophage inflammat

238 ngII-induced expression of cyclooxygenase-2, monocyte chemoattractant protein-1, macrophage inflammat

239 heal had higher tumor necrosis factor-alpha, monocyte chemoattractant protein-1, matrix metallopeptid

240 proteinase 9, metalloproteinase inhibitor 1, monocyte chemoattractant protein-1, P-selectin, fibrinog

241 Expression of tumor necrosis factor-alpha, monocyte chemoattractant protein-1, plasminogen activato

242 e (C-C motif) ligand 2 (CCL2), also known as monocyte chemoattractant protein-1, plays a critical rol

243 isoprostanes, R2 0.07 versus 0.10, P=0.002; monocyte chemoattractant protein-1, R2 0.07 versus 0.08,

244 sis included higher levels of interleukin-8, monocyte chemoattractant protein-1, resistin, soluble in

245 sociated phospholipase A2 mass and activity, monocyte chemoattractant protein-1, soluble endothelial

246 methylarginine, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, soluble vascular cel

247 yed similar up-regulation of miR-132/212 and monocyte chemoattractant protein-1, supporting in vivo r

248 in systolic BP, heart rate variability, and monocyte chemoattractant protein-1, together with reduce

249 nes for interleukin (IL)-1beta, IL-6, IL-10, monocyte chemoattractant protein-1, tumor necrosis facto

250 , intercellular cell adhesion molecule-1 and monocyte chemoattractant protein-1, were also determined

251 idenced by the upregulation of ephrin B2 and monocyte chemoattractant protein-1, which are 2 stretch-

252 oprotein 1 stimulates macrophages to secrete monocyte chemoattractant protein-1, which then activates

253 nd decreased production of oxidant-inducible monocyte chemoattractant protein-1, which we have previo

254 In vitro, IL-6 markedly increased monocyte chemoattractant protein-1-driven monocyte-to-my

255 toreceptor cultures exposed to starvation or monocyte chemoattractant protein-1-stimulated (MCP-1-sti

256 necrosis factor-beta, interferon-gamma, and monocyte chemoattractant protein-1.

257 ming systemic inflammation was the chemokine monocyte chemoattractant protein-1.

258 their migration in response to the chemokine monocyte chemoattractant protein-1.

259 nd secretion of the proinflammatory cytokine monocyte chemoattractant protein-1.

260 th-regulated oncogene-alpha (GRO-alpha), and monocyte chemoattractant protein-1.

261 splanted visceral fat pad and reduced plasma monocyte chemoattractant protein-1.

262 cated in endogenous fat inflammation such as monocyte chemoattractant protein-1.

263 f intercellular cell adhesion molecule-1 and monocyte chemoattractant protein-1.

264 a-like ligand 4, apelin, angiopoietin-2, and monocyte chemoattractant protein-1.

265 nitric oxide synthase 3, thrombomodulin, and monocyte chemoattractant protein-1.

266 crosis factor-alpha) and chemokines (such as monocyte chemoattractant protein-1/ chemokine (C-C motif

267 ssive neuroblastoma, repressed expression of monocyte chemoattractant protein-1/CC chemokine ligand 2

268 n stimulation with CXCL16 astrocytes release monocyte chemoattractant protein-1/CCL2 and (2) the neur

269 leukin-8/C-X-C motif chemokine ligand 8, and monocyte chemoattractant protein-1/chemokine ligand 2 in

270 8/C-X-C motif chemokine ligand 8 P=0.04, and monocyte chemoattractant protein-1/chemokine ligand 2 P=

271 e ASK1-p38 pathway induced expression of the monocyte chemoattractant protein 3 (MCP-3) gene, which p

272 zed by downregulation of chemokines, such as monocyte-chemoattractant protein-5 (MCP-5).

273 The respective ligands, monocyte chemoattractant protein and C-C motif ligand 19

274 ry cytokines, matrix metalloproteinases, and monocyte chemoattractant protein from murine RPE cells.

275 s, Syk signaling increased the expression of monocyte chemoattractant protein MCP-1, which in periphe

276 such as tumor necrosis factor (TNF) -alpha, monocyte chemoattractant protein (MCP) -1, and intercell

277 Mouse CCL8 is a CC chemokine of the monocyte chemoattractant protein (MCP) family whose biol

278 We demonstrate that monocyte chemoattractant protein (MCP)-1 (CCL2) and its

279 sites of microbial infection in response to monocyte chemoattractant protein (MCP)-1 (CCL2) secretio

280 ession of interleukin (IL)-6 (P = 0.010) and monocyte chemoattractant protein (MCP)-1 (P = 0.04) in u

281 ght to determine whether the novel biomarker monocyte chemoattractant protein (MCP)-1 adds prognostic

282 hage-colony-stimulating factor (GM-CSF), and monocyte chemoattractant protein (MCP)-1 and also invasi

283 ion and the level of expression of chemokine monocyte chemoattractant protein (MCP)-1 and by counting

284 To identify signs of neurological disease, monocyte chemoattractant protein (MCP)-1 levels in CSF a

285 onor PAR-1 is required to generate the local monocyte chemoattractant protein (MCP)-1 needed to recru

286 L-13 showed strong correlations with AHR and monocyte chemoattractant protein (MCP)-1 with asthma sev

287 -E8 colocalizes with both angiotensin II and monocyte chemoattractant protein (MCP)-1 within vascular

288 tion by adipocytes of serum amyloid A (SAA), monocyte chemoattractant protein (MCP)-1, and hyaluronan

289 Immunostaining for monocyte chemoattractant protein (MCP)-1, C-C chemokine

290 mokines, including IL-17A, IL17F, IFN-gamma, monocyte chemoattractant protein (MCP)-1, MCP-2, and int

291 vestigate the role of CCR2, the receptor for monocyte chemoattractant protein (MCP)-1, MCP-2, and MCP

292 urpose of this study was to evaluate whether monocyte chemoattractant protein (MCP)-1-activated monoc

293 luding VCAM-1, IL-6, ICAM-1, E-selectin, and monocyte chemoattractant protein (MCP)-1.

294 igomerization propensities of the chemokines monocyte chemoattractant protein (MCP)-1/CCL2 and MCP-3/

295 Monocyte chemoattractant protein (MCP)-1/CCL2 is express

296 expressed and secreted (RANTES), MIG, IP-10; monocyte chemoattractant protein (MCP)-3; eotaxin-1; CCR

297 origin for CFPs, we investigated the role of monocyte chemoattractant protein (MCP1) in mediating CFP

298 and induced a significantly higher degree of monocyte chemoattractant protein production by JR-CSF/hu

299 Monocyte chemoattractant proteins (such as CCL2) are pro

300 erosclerosis was accompanied by increases in monocyte chemoattractant protein type-1, tumor necrosis